Form 4: Cogent Biosciences CFO Granted Stock Options

John L. Green, CFO of Cogent Biosciences, Inc., was granted stock options to purchase 270,000 shares of common stock on January 23, 2025.

Summary

• John L. Green, the Chief Financial Officer of Cogent Biosciences, Inc., was granted stock options on January 23, 2025.
• The options give Green the right to buy 270,000 shares of Cogent Biosciences' common stock at an exercise price of $8.89 per share.
• The stock options vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of four years is also typical, aligning with industry norms for long-term incentives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates